Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib vs Idelalisib/Rituximab or Bendamustine/Rituximab in BTKi-Pretreated CLL/SLL
NCT04666038Phase 3Active, not recruiting
- Sponsor
- Loxo Oncology
- Start
- Mar 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of pirtobrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Loxo Oncology. Started Mar 2021; status: active, not recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04666038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666038.